The development of Brentuximab vedotin has opened a new era in the management of PTCL. The improved outcomes with BV-CHP versus CHOP in the ECHELON-2 trial are practice changing for common nodal CD30+ PTCLs. Questions regarding the optimal cut off of CD30 expression for BV-CHP therapy and the efficacy and safety of BV-CHP in less common subtypes of CD30+ PTCL subtypes await clarification.

This content is only available as a PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.